导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.80% | 1540/4762 |
| 近一周 | -1.21% | 1807/5451 |
| 近一月 | -8.28% | 4864/5408 |
| 近一季 | -18.35% | 4731/5218 |
| 近半年 | -0.57% | 1509/4907 |
| 近一年 | 7.63% | 1443/4387 |
| 近两年 | 109.61% | 546/2950 |
| 近三年 | 65.65% | 403/2249 |
| 成立以来 | 116.39% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.89% 2002/4961 |
35.49% 906/5312 |
- - |
- - |
| 2025 | 48.26% 535/4813 |
-1.54% 2686/3635 |
3.24% 1087/4076 |
47.20% 475/4524 |
-0.92% 2714/4813 |
| 2024 | 13.14% 1170/3463 |
-3.75% 1555/2808 |
-6.02% 1831/3014 |
27.40% 226/3129 |
-1.81% 1840/3463 |
| 2023 | -17.97% 1772/2656 |
1.92% 1483/2280 |
-6.95% 1749/2385 |
-8.96% 1757/2515 |
-4.98% 1227/2655 |
| 2022 | -28.04% 1520/2207 |
-19.16% 1437/1919 |
5.68% 845/2016 |
-17.56% 1616/2113 |
2.17% 1021/2208 |
| 2021 | 11.26% 403/1822 |
-6.65% 1027/1255 |
24.74% 107/1330 |
-6.47% 937/1466 |
2.16% 676/1822 |
| 2020 | 61.67% 121/1250 |
3.91% 101/1022 |
29.10% 83/1060 |
5.47% 911/1152 |
- - |
| 2019 | 41.38% 232/1092 |
32.58% 169/748 |
-9.51% 657/797 |
7.43% 87/844 |
9.69% 204/912 |
| 2018 | -25.77% 363/834 |
- - |
- - |
- - |
-10.04% 173/691 |
| 2017 | -12.53% 553/714 |
- - |
- - |
- - |
- - |
| 2016 | -28.86% 498/605 |
- - |
- - |
- - |
- - |
| 2015 | 71.43% 2/575 |
- - |
- - |
- - |
- - |
| 2014 | 8.81% 213/237 |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国创业板ETF联接A VS. 长安沪深300非周期A(740101) |